Journal of Traditional Medical Complementary Therapies

.: ORIGINAL RESEARCH
Bilim Haritalama Tekniklerine Göre Fitoterapi Kavramı
The Concept of Phytotherapy by Science Mapping Techniques
Mustafa İKİZEKa
aİntegratif Tıp Kliniği, Ankara, TÜRKİYE
J Tradit Complem Med. 2020;3(3):319-30
doi: 10.5336/jtracom.2020-74703
Article Language: TR
Full Text
ÖZET
 Amaç: Bu araştırmanın temel amacı, fitoterapi kavramının tarihsel dönüşümünü, bilim haritalama tekniklerine göre incelemektir. Gereç ve Yöntemler: Veriler, 'Web of Science Core Collection' veri tabanından elde edilmiştir. CiteSpace ve SciMAT yazılımları ile 1990- 2019 yıllarına ait 1.326 makale analiz edilmiştir. SciMAT yazılımı ile 3 döneme (1990-1999, 2000-2009 ve 2010-2019) özgü stratejik diyagram ve stratejik gelişim haritası elde edilmiştir. CiteSpace yazılımında ise zaman haritası ve atıf patlaması yapan çalışmalar analiz edilmiştir. Bulgular: Fitoterapi alanında en fazla sayıda araştırma Brezilya (n=275), Almanya (n=220) ve İtalya (n=122) tarafından yapılmıştır. En fazla sayıda makale (n=122), 2017 yılında yayımlanmıştır. Stratejik diyagramlardan 1990-1999 döneminde 4 motor tema, 2000-2009 döneminde 6 motor tema, 2010-2019 döneminde ise 9 motor tema elde edilmiştir. Stratejik gelişim haritası açısından bakıldığında ise fitoterapi biliminin gelişiminin devam ettiği ve derinlik kazandığı görülmektedir. Atıf patlaması yapan 27 çalışma tespit edilmiştir. Zaman haritası analizinde ise anlamlı 3 büyük küme belirlenmiştir. Sonuç: Politika yapıcılar ve kaynak dağıtım kanalları, son dönem verilerine dayalı motor temalarına teşvik eden düzenlemeler yapabilir. Fitoterapi konusunda; stratejik diyagram, tematik gelişim haritalama ve tematik ağ diyagramları ile ortaya konulan bilimsel haritalamanın, konuya ilgi duyan tüm paydaşlar ve akademisyenler açısından incelemesi gereken önemli bir bilgi kaynağı olabileceği değerlendirilmektedir.

Anahtar Kelimeler: Fitoterapi; alternatif tıp; bilim haritalama
ABSTRACT
 Objective: The main purpose of this research is to examine the historical transformation of the concept of phytotherapy with science mapping techniques. Material and Methods: The data were obtained from the Web of Science Core Collection database. 1,326 articles from 1990-2019 were analyzed with CiteSpace and SciMAT software. Strategic diagram and strategic development map specific to three periods (1990-1999, 2000-2009 and 2010-2019) were obtained with SciMAT software. In the CiteSpace software, the time map and citation explosion studies were analyzed. Results: The highest number of studies in phytotherapy field was done by Brazil (n=275), Germany (n=220) and Italy (n=122). The highest number of articles were published in 2017 (n=122). From the strategic diagrams, 4 motor themes in the 1990-1999 period, 6 motor themes in the 2000-2009 period and 9 motor themes in the 2010-2019 period were obtained. From the perspective of the strategic development map, it is seen that the development of phytotherapy science continues and gains depth. 27 studies that identified citation burst were identified. Three significant clusters were identified in the time map analysis. Conclusion: Policymakers and resource distribution channels can make arrangements to promote motor themes based on recent data. In phytotherapy; strategic mapping, thematic development mapping and thematic network diagrams are considered to be an important source of information for all interested stakeholders and academics.

Keywords: Phytotherapy; alternative medicine; science mapping
REFERENCES:
  1. Menin A. Henri Leclerc and the birth of modern phytotherapy. Eur J Integr Med. 2012;4:187.[Crossref] 
  2. Falzon CC, Balabanova A. Phytotherapy: an introduction to herbal medicine. Prim Care. 2017;44(2):217-27.[Crossref] [PubMed] 
  3. Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy: A Quick Reference to Herbal Medicine. 1st ed. Germany: Springer Science & Business Media; 2003. p.1-424.[Crossref] 
  4. Gupta RC. Nutraceuticals: Efficacy, Safety and Toxicity. 1st ed. Amsterdam: Elsevier, Academic Press; 2016. p.1-1040.
  5. Odugbemi T. Outlines and Pictures of Medicinal Plants from Nigeria. 1st ed. Lagos, Nigeria: University of Lagos Press; 2008. p.1-283.
  6. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12(1):122-32.[Crossref] [PubMed] 
  7. Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res. 2000;33(2):179-89.[Crossref] [PubMed] 
  8. Petkova V, Hadzhieva B, Nedialkov P. Phytotherapeutic approaches to treatment and prophylaxis in pediatric practice. Pharmacia. 2019;66(3):115-9.[Crossref] 
  9. Nwabueze RN. Biotechnology and the Challenge of Property: Property Rights in Dead Bodies, Body Parts, and Genetic Information. 1st ed. An Ashgate Book, UK.: Routledge; 2016. p.1-392.[Crossref] [PMC] 
  10. Hou W. Treating Autoimmune Disease with Chinese Medicine. 1st ed. London: Elsevier Health Sciences; 2009. p.1-320.
  11. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.[Crossref] [PubMed] [PMC] 
  12. Fürst R, Zündorf I. Evidence-based phytotherapy in Europe: Where do we stand? Planta Med. 2015;81(12-13):962-7.[Crossref] [PubMed] 
  13. Herbal medicine market size and forecast, by product (tablets & capsules, powders, extracts), by ındication (digestive disorders, respiratory disorders, blood disorders), and trend analysis, 2014-2024. Industry Report. Hexa Research. 2017.[Link] 
  14. Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol. 2007;3(7):360-6.[Crossref] [PubMed] 
  15. Noras M, Yousefi M, Kiani MA. Complementary and alternative medicine (CAM) use in pediatric disease: a short review. Int J Pediatr. 2013;1(2):45-9.[Link] 
  16. Clements DS, Ring M, Shah A. Integrative Medicine, An Issue of Primary Care: Clinics in Office Practice. Primary care: clinics in office practice, Vol 44, No 2. 1st ed. Philadelphia, PA: Elsevier; 2017. p.203-377.[Crossref] 
  17. Dutt B, Kumar S, Garg KC. Mapping of plant-based medicine research in China and India. Research Evaluation. 2009;18(1):51-9.[Crossref] 
  18. Fu JY, Zhang X, Zhao YH, Chen DZ, Huang MH. Global performance of traditional Chinese medicine over three decades. Scientometrics. 2012;90(3):945-58.[Crossref] 
  19. SciMAT. (Erişim tarihi: 15.12.2019)[Link] 
  20. CiteSpace. (Erişim tarihi: 30.12.2019)[Link] 
  21. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29(4):231-40.[Crossref] [PubMed] 
  22. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280(18):1604-9.[Crossref] [PubMed] 
  23. Buck AC. Phytotherapy for the prostate. Br J Urol. 1996;78(3):325-36.[Crossref] [PubMed] 
  24. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-9.[Crossref] [PubMed] 
  25. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 2000;55(4):533-9.[Crossref] [PubMed] 
  26. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9(5):379-95.[Crossref] [PubMed] 
  27. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999;53(4):671-8.[Crossref] [PubMed] 
  28. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497-506.[Crossref] [PubMed] 
  29. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995;9:291-7.[Crossref] 
  30. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol. 1998;33(3):340-7.[Crossref] [PubMed] 
  31. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557-66.[Crossref] [PubMed] 
  32. Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995;54(5-6):273-9.[Crossref] [PubMed] 
  33. Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol. 1995;48(1):97-103.[PubMed] 
  34. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993;22(1):43-51.[Crossref] [PubMed] 
  35. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37(2):77-83.[Crossref] [PubMed] 
  36. Pieroni A, Quave C, Nebel S, Heinrich M. Ethnopharmacy of the ethnic Albanians (Arbëreshë) of northern Basilicata, Italy. Fitoterapia. 2002;73(3):217-41.[Crossref] [PubMed] 
  37. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48(1):12-20.[Crossref] [PubMed] 
  38. Antonio GD, Tesser CD, Moretti-Pires RO. [Phytotherapy in primary health care]. Rev Saude Publica. 2014;48(3):541-53.[Crossref] [PubMed] [PMC] 
  39. Pieroni A, Quave CL. Traditional pharmacopoeias and medicines among Albanians and Italians in southern Italy: a comparison. J Ethnopharmacol. 2005;101(1-3):258-70.[Crossref] [PubMed] 
  40. Scherrer AM, Motti R, Weckerle CS. Traditional plant use in the areas of Monte Vesole and Ascea, Cilento National Park (Campania, Southern Italy). J Ethnopharmacol. 2005;97(1):129-43.[Crossref] [PubMed] 
  41. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-51.[Crossref] [PubMed] [PMC] 
  42. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999;40(4):232-41.[Crossref] [PubMed] 
  43. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997;80(3):427-32.[Crossref] [PubMed] 
  44. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995;345(8964):1529-32.[Crossref] [PubMed] 
  45. Pieroni A, Muenz H, Akbulut M, Başer KH, Durmuşkahya C. Traditional phytotherapy and trans-cultural pharmacy among Turkish migrants living in Cologne, Germany. J Ethnopharmacol. 2005;102(1):69-88.[Crossref] [PubMed] 
  46. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46(5):547-54.[Crossref] [PubMed] 
  47. Pieroni A, Nebel S, Quave C, Münz H, Heinrich M. Ethnopharmacology of liakra: traditional weedy vegetables of the Arbëreshë of the Vulture area in southern Italy. J Ethnopharmacol. 2002;81(2):165-85.[Crossref] [PubMed] 
  48. Greiner KA, Murray JL, Kallail KJ. Medical student interest in alternative medicine. J Altern Complement Med. 2000;6(3):231-4.[Crossref] [PubMed] 
  49. Loh KP, Ghorab H, Clarke E, Conroy R, Barlow J. Medical students' knowledge, perceptions, and interest in complementary and alternative medicine. J Altern Complement Med. 2013;19(4):360-6.[Crossref] [PubMed] 
  50. da Rosa C. Traditional medicine and complementary/alternative medicine in primary health care: The Brazilian experience. In: Capelli O, ed. Primary Care at a Glance - Hot Topics and New Insights. Books on Demand; 2012.[Crossref] 
  51. De Natale A, Pollio A. Plants species in the folk medicine of Montecorvino Rovella (inland Campania, Italy). J Ethnopharmacol. 2007;109(2):295-303.[Crossref] [PubMed] 
  52. Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000;3(4A):459-72.[Crossref] [PubMed] 
  53. Sawyer D. Economic and social consequences of malaria in new colonization projects in Brazil. Soc Sci Med. 1993;37(9):1131-6.[Crossref] [PubMed] 
  54. Arslan N. [Medical and aromatic plants]. Türkiye Tohumcular Birliği Dergisi. 2016;17(5):66-9.[Link] 
  55. Nandhini S, Narayanan KB, Ilango K. Valeriana officinalis: a review of its traditional uses, phytochemistry and pharmacology. Asian J Pharm Clin Res. 2018;11(1):36-41.[Crossref] 
  56. Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67(6):1281-3.[PubMed] 
  57. Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015;94(2):187-93.[Crossref] [PubMed] 
  58. Robert GY. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammatory biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14(9):1470-4.[Crossref] 
  59. Parildar H, Serter R, Yesilada E. Diabetes mellitus and phytotherapy in Turkey. J Pak Med Assoc. 2011;61(11):1116-20.[PubMed] 
  60. Tepe B, Sokmen M, Akpulat HA, Sokmen A. In vitro antioxidant activities of the methanol extracts of five Allium species from Turkey. Food Chemistry. 2005;92(1):89-92.[Crossref] 
  61. Web of Science. (Erişim tarihi: 15.12.2019)[Link] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com